Retrospective study shows clinical characteristics and outcomes in patients with dual T- and B-cell malignancies, highlighting clonal hematopoiesis risks.
Key Points
To evaluate the clinical features and outcomes of patients with dual primary T-cell and B-cell malignancies.
Ongoing retrospective study across multiple academic centers
Inclusion of patients over 18 with dual mature T-cell and B-cell neoplasms
Analysis of clinical characteristics and outcomes, including median age and comorbid conditions
Identified 40 patients with dual B- and T-cell lymphoid malignancies
60% were male and the median age at diagnosis was 64 years
Autoimmune conditions noted in 20% of patients; mutations in TET2 observed in 20%